சுவாச நோய்த்தொற்றுகள் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from சுவாச நோய்த்தொற்றுகள். Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In சுவாச நோய்த்தொற்றுகள் Today - Breaking & Trending Today

Affinivax and Astellas Present Safety and Immunogenicity Data from Phase 2 Study of ASP3772, a Novel


Search jobs
12-Jul-2021
Affinivax and Astellas Present Safety and Immunogenicity Data from Phase 2 Study of ASP3772, a Novel 24 valent MAPS™ Vaccine for Streptococcus pneumoniae
Study results were selected for oral presentation at the 31st European Congress of Clinical Microbiology & Infectious Diseases (ECCMID)
ASP3772 has also received FDA Breakthrough Therapy Designation
CAMBRIDGE, Mass. & TOKYO (BUSINESS WIRE) Affinivax, Inc. ( Affinivax ) and Astellas Pharma Inc. (“Astellas”) announced results from the Phase 2 clinical trial of ASP3772, a novel vaccine candidate targeting
Streptococcus pneumoniae. Developed using Affinivax’s proprietary MAPS™ (Multiple Antigen-Presenting System) platform technology, ASP3772 is designed to offer both B-cell (antibody) and T-cell immune protection against ....

United Kingdom , United States , Stevenb Brugger , Salim Mujais , Kathryn Morris , Yates Network , Astellas Pharma Inc , European Congress , Drug Administration , Melinda Gates Foundation , National Foundation For Infectious Disease , Affinivax Inc , Clinical Microbiology , Infectious Diseases , Astellas Pharma , Multiple Antigen Presenting System , Breakthrough Therapy , Senior Vice President , Therapeutic Area Head , Medical Specialties , National Foundation , Infectious Disease , Boston Children , Focus Area Approach , Respiratory Infections , Global Burden ,